EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How I Treat: Haploinsufficiency of A20

Jonathan Li iD, Jeffrey Y Zhou iD, Manuel Carpio Tumba iD, Tingyan He iD, Kader Cetin Gedik iD, Daniella M Schwartz iD

Journal of Human Immunity · 06.07.2026 · 2 (4)

DOI: 10.70962/jhi.20250138 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Human Immunity, online erschienen am 04.05.2026. Verfasst von Jonathan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Jeffrey Modell Foundation, Rheumatology Research Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haploinsufficiency of A20 (HA20) is a primary immune regulation disease caused by heterozygous loss-of-function variants in TNFAIP3, resulting in unchecked inflammatory signaling. HA20 is a highly heterogeneous disorder with overlapping features of autoinflammation, autoimmunity, immunodeficiency, atopy, and lymphoproliferation. Most patients develop symptoms in early childhood mimicking Behcet’s disease, inflammatory bowel disease, periodic fevers with aphthous stomatitis, pharyngitis, and adenopathy (PFAPA), systemic lupus erythematosus (SLE), autoimmune hepatitis, vasculitis, and other conditions. This phenotypic variability contributes to diagnostic delays. Diagnosis requires identification of a pathogenic TNFAIP3 variant or deletion encompassing TNFAIP3: most are null, but missense variant interpretation remains challenging. After diagnosis, we use comprehensive clinical laboratory studies, imaging, and multidisciplinary evaluations to screen for complications. Treatment is guided by clinical phenotype and biomarkers. Colchicine and PDE4 inhibitors may control mild disease, whereas IL-1, TNF, and JAK inhibitors are often necessary for moderate-severe cases. Acute withdrawal of immunosuppression can precipitate disease flares. Genetic counseling and evaluation of at-risk family members are essential.

Autor:innen und Institutionen

  • Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Autoinflammatory Center of Excellence, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Pittsburgh Immunogenetics Discovery Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Division of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China.
  • Division of Pediatric Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

ORCID-Profile: Jonathan Li, Jeffrey Y Zhou, Manuel Carpio Tumba, Tingyan He, Kader Cetin Gedik, Daniella M Schwartz

Förderung

  • NICHD NIH HHS
  • Jeffrey Modell Foundation
  • Rheumatology Research Foundation

Zitieren

APA

Li, J., Zhou, J. Y., Carpio Tumba, M., He, T., Cetin Gedik, K., & Schwartz, D. M. (2026). How I Treat: Haploinsufficiency of A20. Journal of Human Immunity, 2(4). https://doi.org/10.70962/jhi.20250138

Vancouver

Li J, Zhou JY, Carpio Tumba M, He T, Cetin Gedik K, Schwartz DM. How I Treat: Haploinsufficiency of A20. Journal of Human Immunity. 2026;2(4). doi:10.70962/jhi.20250138

BibTeX
@article{Li2026,
  author = {Li, Jonathan and Zhou, Jeffrey Y and Carpio Tumba, Manuel and He, Tingyan and Cetin Gedik, Kader and Schwartz, Daniella M},
  title = {How I Treat: Haploinsufficiency of A20},
  journal = {Journal of Human Immunity},
  year = {2026},
  volume = {2},
  number = {4},
  doi = {10.70962/jhi.20250138}
}
Kostenlos starten →